7.72
0.32 (4.32%)
| Penutupan Terdahulu | 7.40 |
| Buka | 7.16 |
| Jumlah Dagangan | 18,855 |
| Purata Dagangan (3B) | 36,267 |
| Modal Pasaran | 28,195,600 |
| Harga / Jualan (P/S) | 3.36 |
| Harga / Buku (P/B) | 2.94 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Mar 2025 - 31 Mar 2025 |
| Margin Keuntungan | -122.46% |
| Margin Operasi (TTM) | -65,066.67% |
| EPS Cair (TTM) | -2.62 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -99.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.18% |
| Nisbah Semasa (MRQ) | 10.68 |
| Aliran Tunai Operasi (OCF TTM) | -10.72 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -5.20 M |
| Pulangan Atas Aset (ROA TTM) | -20.34% |
| Pulangan Atas Ekuiti (ROE TTM) | -70.96% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Pulmatrix, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -1.67 |
|
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.65% |
| % Dimiliki oleh Institusi | 9.01% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Highline Wealth Partners Llc | 30 Sep 2024 | 0 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 21 Mar 2025 | Pengumuman | Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets |
| 22 Jan 2025 | Pengumuman | Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |